Ozempic Hair Loss: Why It Happens and 6 Nutrients That Help (2026)

How Common Is Hair Loss on GLP-1 Drugs?

Real-world studies report hair loss in 39% to 77% of GLP-1 users, far more than the 3% reported in the original Wegovy clinical trials. The number depends heavily on the drug, the rate of weight loss, and the population studied.

In the pivotal Wegovy (semaglutide 2.4 mg) weight-management trial, hair loss was reported by 3% of participants versus 1% on placebo. That number shaped early clinical expectations. But as prescriptions surged, the KFF Health Tracking Poll from November 2025 found 12% of US adults now take a GLP-1 drug. Real-world data began painting a different picture.

A cross-sectional survey of 504 GLP-1 users in the United States, published in the Journal of Cosmetic Dermatology in August 2026, found that 38.9% reported hair changes — 20.8% experienced active shedding and 19.0% noticed thinning. Among those who lost 40 pounds or more, 57% reported both shedding and thinning. The study also found racial differences: White users more commonly experienced classic telogen effluvium-type shedding, while Black/African American users reported higher rates of dryness and breakage (Olivero et al., J Cosmet Dermatol, 2026).

A separate Saudi Arabian cross-sectional study of GLP-1 users, published in January 2026, found that hair shedding affected roughly seven out of ten users, a tenfold increase over registration trial reports. Tirzepatide (Mounjaro) users had the highest prevalence at 76.7%, followed by semaglutide at 64% (PMID 41799300, Skin Appendage Disord, 2026).

Then came the largest study to date. Published in The BMJ on July 22, 2026, researchers at the University of Pennsylvania analyzed data from nearly 40,000 patients with type 2 diabetes. GLP-1 users had a 53% higher risk of alopecia compared to SGLT-2 inhibitor users and a 72% higher risk compared to DPP-4 inhibitor users (University of Pennsylvania, BMJ, 2026). The UK's MHRA received close to 400 hair-loss reports for tirzepatide in 2026 alone, plus 148 for semaglutide.

The bottom line: if you are shedding hair on a GLP-1, you are not in a small minority. And the evidence now strongly suggests this is a real, measurable side effect. Not just anecdote.

Why Does Ozempic Cause Hair Shedding?

The mechanism is telogen effluvium (TE) — a temporary disruption of the hair growth cycle triggered by physiological stress. Here is what happens step by step:

Your hair grows in three phases: anagen (growth, 2–7 years), catagen (transition, 2–3 weeks), and telogen (rest and shedding, about 3 months). Normally, roughly 85–90% of your hairs are in anagen at any given time. When your body encounters a major stressor, rapid weight loss, caloric restriction, nutritional depletion, hormonal shifts. It diverts resources away from hair follicles. Up to 30% of hairs can get pushed into telogen prematurely.

Two to four months later, those telogen hairs fall out. That is the shedding you notice in the shower drain or on your pillow.

A 2026 systematic review in Science Progress confirmed that telogen effluvium was the predominant subtype of hair loss reported across GLP-1 studies. Tirzepatide, which produces the largest magnitude of weight loss, was most frequently linked to TE (GLP-1 and hair loss review, Sci Prog, 2026).

The key drivers on a GLP-1 drug are:

Rapid weight loss. Losing weight quickly, particularly more than 1–2 pounds per week, is the strongest trigger. (Rapid loss also drives muscle loss and fatigue through the same mechanism.) The 2026 Saudi study found that greater weight loss correlated with higher hair-loss severity. This pattern is well-documented after bariatric surgery, where TE rates range from 30% to 57%.

Reduced caloric and nutrient intake. GLP-1 drugs suppress appetite. Adults on semaglutide eat 20–35% fewer calories per day. That reduction cuts intake of iron, zinc, B12, protein, vitamin D, and folate. All of which are required for keratin synthesis and follicle cycling.

Hormonal shifts. Rapid fat loss alters levels of thyroid hormones, sex hormones, and cortisol — each of which influences the hair cycle. Even subtle thyroid changes can push hairs into telogen.

The good news: telogen effluvium is not scarring. The follicles are not destroyed. In the 2025 Saudi study, 40.3% of participants reported that their hair loss had stabilized over time, suggesting the body adapts as weight loss slows.

6 Nutrients That Support Hair During GLP-1 Treatment

The six nutrients most consistently linked to hair recovery on a GLP-1 are iron, zinc, vitamin B12, protein, vitamin D, and folate. All six decline when food intake drops 20 to 35% on appetite-suppressing medication.

The six nutrients most consistently linked to hair recovery on a GLP-1 are iron, zinc, vitamin B12, protein, vitamin D, and folate. All six decline when appetite drops and food intake falls 20 to 35%.

A 2026 systematic review in Science Progress identifies the following as key preventive nutrients: "adequate protein, iron, zinc, vitamin D, B12, and [vitamin] A." A 2019 comprehensive review of the role of diet and nutrients in hair loss, published in Dermatology and Therapy, found iron, zinc, biotin, and vitamin D were the most studied nutrients for diffuse thinning (Almohanna et al., Dermatol Ther, 2019; PMID 30547302).

Here are the six nutrients with the strongest evidence, ranked by relevance to GLP-1 users:

1. Iron (Ferritin)

Iron is the single most studied nutrient in telogen effluvium. Ferritin, your body's iron storage protein, below 40 ng/mL is consistently associated with increased shedding. A controlled study of 381 women at the Duke University Hair Disorders Clinic found iron deficiency was common across telogen effluvium and female pattern hair loss groups (Olsen et al., J Am Acad Dermatol, 2010). On a GLP-1, red meat and iron-rich food intake drops with overall calorie reduction.

What to do: Ask your doctor for a ferritin test before or soon after starting a GLP-1. If below 40 ng/mL, supplementation with iron bisglycinate (the most GI-friendly form) may help. A typical dose is 18–27 mg elemental iron daily — the same amount included in most GLP-1 companion supplements.

2. Zinc

Zinc is essential for keratin synthesis and follicle cell division. Deficiency disrupts the hair cycle and is a recognized cause of telogen effluvium independent of weight loss. A 2025 cross-sectional study found lower zinc levels were associated with hair loss complaints, particularly in telogen effluvium (Hair Loss and Zinc Deficiency, Healthcare (Basel), 2025). A post-COVID TE study found that patients who supplemented with zinc during their illness had significantly lower rates of subsequent hair shedding (Post-COVID TE study, Arch Dermatol Res, 2024).

What to do: 15–20 mg of zinc daily. Zinc competes with iron for absorption, so take them at different times of day if supplementing both.

3. Vitamin B12 (Methylcobalamin)

B12 plays a role in red blood cell formation, which delivers oxygen to hair follicles. Reduced food intake on a GLP-1 drug frequently leads to suboptimal B12 levels, especially in patients who already eat less meat. The 2025 Joint Advisory from four major medical societies (ACLM, ASN, OMA, and TOS) on nutritional priorities during GLP-1 therapy specifically highlights B12 monitoring as a priority.

What to do: Methylcobalamin (the active form) at 500–1000 mcg daily. This is included in most quality GLP-1 companion formulas.

4. Protein

Hair is 80–85% keratin, a protein. When protein intake drops, the body prioritizes vital organs over hair. The 2026 Science Progress systematic review states directly: GLP-1 RA use is associated with "insufficient dietary … protein," and that maintaining adequate protein is a primary preventive strategy.

What to do: Target at least 60 g of protein per day, ideally 1.0–1.2 g per kg of body weight. This is challenging on suppressed appetite, prioritize protein at every meal. Protein shakes, Greek yogurt, eggs, and cottage cheese are efficient sources when solid food volume is difficult.

5. Vitamin D

Vitamin D receptors are present in hair follicles and play a role in anagen initiation. Deficiency is already common in the general population (roughly 42% of US adults have levels below 20 ng/mL) and worsens with caloric restriction.

What to do: 1000–2000 IU of vitamin D3 daily. Get a 25-hydroxyvitamin D blood test. Optimal range for hair health is generally considered 40–60 ng/mL.

6. Folate (5-MTHF)

Folate supports cell division in rapidly turning-over tissues, including hair follicles. The methylated form (5-MTHF) is preferable because roughly 40% of the population carries MTHFR variants that reduce conversion of folic acid. The Joint Advisory on GLP-1 nutritional priorities includes folate among the micronutrients requiring monitoring.

What to do: 400–800 mcg of 5-MTHF daily, or a comprehensive GLP-1 companion formula that includes it alongside the other nutrients above.

What About Biotin?

Biotin (vitamin B7) is the most heavily marketed "hair vitamin," but evidence for supplementation in people without a diagnosed biotin deficiency is weak. The Almohanna 2019 review notes that while biotin deficiency causes hair loss, true deficiency is rare in people eating a varied diet — even a reduced one.

If you are already taking a B-complex or companion formula, you likely have adequate biotin.

More importantly: high-dose biotin (>5000 mcg) can interfere with lab tests, including thyroid panels, troponin, and hormone assays. If your doctor is monitoring your thyroid on a GLP-1, and they should be. Taking mega-dose biotin can produce falsely abnormal results. Stick to 30–100 mcg (the daily adequate intake range) unless specifically directed otherwise.

Timeline: When Does Shedding Start and Stop?

Hair shedding typically begins 2 to 4 months after starting a GLP-1 drug, peaks around months 3 to 6, and resolves within 3 to 6 months once weight loss stabilizes and nutritional gaps are corrected. Here is the detailed breakdown based on clinical data:

Onset: 2–4 months after starting the medication (or after a period of rapid weight loss). In the Olivero 2026 survey, 42% of those experiencing shedding said it began within 1–3 months.

Peak: Typically around months 3–6, coinciding with the maximum rate of weight loss.

Stabilization: In the 2025 Saudi study, 40.3% of users reported that hair loss had stabilized — suggesting the shedding slows as weight loss decelerates and the body adapts.

Recovery: If nutritional gaps are addressed and weight loss stabilizes, regrowth usually begins within 3–6 months after the trigger resolves. New hairs may initially come in finer and shorter, with full density taking 6–12 months to return.

If shedding persists beyond 6 months despite nutritional correction, ask your dermatologist to evaluate for other causes, including underlying androgenetic alopecia, thyroid dysfunction, or iron-deficiency anemia that may be unmasking alongside the telogen effluvium.

Who Is Most at Risk?

Women, people losing weight rapidly, those on higher doses or tirzepatide, and anyone with low baseline iron or vitamin D are at highest risk for hair loss on a GLP-1. The research consistently identifies these risk factors:

Women are more affected than men. The Sodhi 2025 study found semaglutide-associated hair loss was more common in women (Sodhi et al., medRxiv, 2025). The Olivero 2026 survey (504 participants, 72.8% female) reported shedding and thinning rates that skew heavily female. Biologically, this makes sense: women have lower baseline iron stores and are more susceptible to telogen effluvium at any age.

Greater weight loss = greater risk. Olivero et al. found that 57% of those losing ≥40 lb reported both shedding and thinning, compared to lower rates at lesser weight loss.

Rapid titration. The Science Progress review recommends gradual dose escalation to minimize rapid metabolic shifts.

Pre-existing low nutrient status. Anyone entering GLP-1 treatment with low ferritin, vitamin D deficiency, or marginal protein intake is at elevated risk. And this describes a large portion of the overweight/obese population.

5 Steps to Minimize Hair Loss on a GLP-1

Get baseline labs before starting. Prioritize protein at every meal (60+ g/day). Take a targeted companion supplement with iron, zinc, and B12. Ask about slower dose titration. Monitor and be patient — telogen effluvium is reversible in most cases.

Step 1: Get baseline labs before starting. Request ferritin, vitamin D (25-OH), B12, zinc, CBC, and a thyroid panel. Correct any deficiency before shedding begins — once TE starts, you are already 2–4 months behind.

Step 2: Prioritize protein at every meal. Aim for 60+ grams per day, minimum. This is the single most impactful dietary step. When appetite is suppressed, protein-first eating ensures you get the macronutrient your hair (and muscle) need most.

Step 3: Take a targeted companion supplement. For a full overview of which supplements fill the gaps GLP-1 drugs create, see our guide to the best GLP-1 companion supplements. A formula designed for GLP-1 users, containing iron bisglycinate, zinc, methylcobalamin B12, vitamin D3, 5-MTHF folate, and digestive enzymes. Addresses the specific nutritional gaps created by reduced food intake. Generic multivitamins often lack adequate iron or use poorly absorbed forms.

Step 4: Slow down if possible. If your prescriber is flexible, a slower titration schedule may reduce the metabolic shock that triggers TE. Losing 1–2 lb per week rather than 3–4 lb significantly reduces hair-cycle disruption.

Step 5: Be patient and monitor. Telogen effluvium is temporary in the vast majority of cases. Keep tracking your labs at 3 and 6 months. If shedding worsens or does not improve after nutritional correction, request a dermatology referral for trichoscopy to rule out other causes.

GLP-1 Hair Loss vs. Other Types: How to Tell the Difference

Most GLP-1 hair loss is telogen effluvium: diffuse, all-over thinning without bald patches, starting 2-4 months after beginning the drug. Patterned loss (receding hairline, widening part) may indicate androgenetic alopecia being unmasked. The distinction matters because the treatment differs.

Not all hair loss on a GLP-1 is telogen effluvium. Understanding the pattern helps you and your doctor respond correctly.

Telogen effluvium (most common on GLP-1s): Diffuse, all-over thinning. You notice more hairs in the shower, on your brush, and on your pillow, but no bald patches or receding hairline. Hair comes out easily when gently tugged. The Olivero 2026 survey found this was the dominant pattern in White users: 23.8% reported classic shedding, 22.6% reported diffuse thinning.

Androgenetic alopecia (may be unmasked): Patterned loss — widening part in women, receding temples or crown thinning in men. Rapid weight loss can unmask a genetic predisposition that was previously less visible. A June 2026 study found GLP-1 drugs may increase hair-loss risk by 7% in men already genetically susceptible to male-pattern baldness. If your shedding follows a pattern rather than diffuse thinning, this may be a factor.

Structural hair changes: The Olivero survey revealed that Black/African American GLP-1 users reported disproportionately higher rates of dryness (15.3%) and breakage (12.1%) rather than classic shedding, suggesting nutritional deficiency affects hair texture and strength in addition to the growth cycle. This is important because breakage-type loss requires different care (protein treatments, gentle handling, moisture) alongside internal nutrition.

Alopecia areata (rare): Patchy, coin-sized bald spots. This is an autoimmune condition that is occasionally reported alongside GLP-1 use but is not clearly caused by the drug. The 2025 FAERS pharmacovigilance review found disproportionality signals for alopecia with semaglutide and tirzepatide, but the database cannot distinguish subtypes reliably (Cureus systematic review, 2025; DOI 10.7759/cureus.92454).

A simple self-check: run your fingers through your hair and gently pull about 60 hairs. If more than 6 come out (>10%), that suggests active telogen effluvium. If the pattern is diffuse and started 2–4 months after beginning your GLP-1, the diagnosis is usually straightforward. If the pattern is localized or persists beyond 6 months, a dermatologist can perform trichoscopy to differentiate.

What the Latest Research Says (2026 Update)

The science on GLP-1 hair loss has advanced rapidly. Here is what the most current evidence shows:

The BMJ, July 2026: The largest controlled study to date. University of Pennsylvania researchers compared 12,004 GLP-1 users against 15,221 SGLT-2 inhibitor users and 11,964 against 11,233 DPP-4 inhibitor users. GLP-1s carried a statistically significant 53–72% higher risk of alopecia. The researchers concluded that reduced caloric intake is the "most likely mechanism," though they noted more research is needed to rule out direct drug effects.

FAERS 10-year review, J Cosmet Dermatol, 2026: A pharmacovigilance analysis of FDA adverse event reports found disproportionality signals for both semaglutide (Reporting Odds Ratio 1.55 in 2024) and tirzepatide (ROR 2.08 in 2025). Among semaglutide reports with available follow-up, 25% showed improvement after stopping the drug, 19% did not improve, and 18% experienced recurrence when restarting. Providing some evidence of a drug-specific effect beyond just weight loss.

Clinical trials in progress: At least two registered clinical trials (NCT07783113 and NCT07484061) are now testing dietary supplements specifically for GLP-1-associated telogen effluvium. One is a 48-patient single-arm study testing a vitamin/mineral/amino acid formula over 120 days. The other is a 40-patient randomized, double-blind, placebo-controlled trial testing a drinkable multi-ingredient formula in women over 45 taking GLP-1/GIP agonists. Results are expected in 2027 — these will be the first controlled data on whether targeted supplementation actually speeds hair recovery in this population.

Joint Advisory from four medical societies, 2025: The American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society jointly published nutritional priorities for GLP-1 therapy, listing "prevention and mitigation of nutrient deficiencies" as a core priority and noting that protein intake alone may be insufficient to prevent muscle and tissue loss without resistance training.

When to See a Doctor

Mild, diffuse shedding in the 2–6 month window after starting a GLP-1 is expected and usually self-resolving. See a healthcare provider if:

• Shedding is severe (clumps, visible scalp patches, more than a handful daily)
• It continues beyond 6 months despite nutritional support
• You notice a pattern (receding hairline, widening part) rather than diffuse thinning, this may indicate androgenetic alopecia being unmasked
• You develop other symptoms: fatigue, cold intolerance, brittle nails, or rapid heartbeat (which may suggest thyroid or iron issues)

Does everyone lose hair on Ozempic?

No. Clinical trials reported hair loss in about 3% of semaglutide users, though real-world surveys suggest 39–76% experience some degree of shedding or thinning. The severity varies widely. Many people notice only mild, temporary thinning that resolves on its own.

Is Ozempic hair loss permanent?

In the vast majority of cases, no. Telogen effluvium is a temporary disruption of the hair growth cycle, not permanent follicle damage. Once the trigger (rapid weight loss, nutritional gaps) stabilizes, most people see regrowth within 3–6 months. If shedding persists beyond 6 months, see a dermatologist to rule out other causes.

Does Mounjaro cause more hair loss than Ozempic?

Possibly. The 2026 Saudi study found tirzepatide (Mounjaro) users reported hair shedding at 76.7% versus 64% for semaglutide users. Tirzepatide also produces greater weight loss on average, which likely explains the higher rate — the shedding appears driven by the magnitude and speed of weight loss rather than the drug molecule itself.

Will taking biotin stop hair loss on Ozempic?

Probably not on its own. True biotin deficiency is rare, and mega-dose biotin supplements (5000+ mcg) can interfere with blood tests including thyroid panels. Iron, zinc, protein, and B12 are more likely to be the limiting nutrients on a GLP-1 drug. If you take biotin, keep it at the adequate intake level (30–100 mcg) as part of a broader formula.

Should I stop taking Ozempic if I'm losing hair?

Do not stop any prescription medication without discussing it with your prescribing doctor. In most cases, hair loss can be managed with nutritional support and patience while continuing treatment. Your doctor may adjust your dose or slow the titration if shedding is severe. The weight-management and metabolic benefits of GLP-1 therapy should be weighed against temporary cosmetic side effects.

What vitamins should I take on Ozempic to prevent hair loss?

The nutrients most consistently identified in research are iron (as bisglycinate, 18–27 mg), zinc (15–20 mg), methylcobalamin B12 (500–1000 mcg), vitamin D3 (1000–2000 IU), folate as 5-MTHF (400–800 mcg), and adequate dietary protein (60+ g/day). A GLP-1-specific companion supplement that combines these in bioavailable forms is more targeted than a generic multivitamin.